WO2004083250A9 - フォンビルブランド因子特異的切断酵素に対する抗体の認識領域からなる構成物 - Google Patents
フォンビルブランド因子特異的切断酵素に対する抗体の認識領域からなる構成物Info
- Publication number
- WO2004083250A9 WO2004083250A9 PCT/JP2004/003602 JP2004003602W WO2004083250A9 WO 2004083250 A9 WO2004083250 A9 WO 2004083250A9 JP 2004003602 W JP2004003602 W JP 2004003602W WO 2004083250 A9 WO2004083250 A9 WO 2004083250A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- polypeptide
- adamts
- patient
- peptide fragment
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 33
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 33
- 102100036537 von Willebrand factor Human genes 0.000 title claims abstract description 16
- 108010047303 von Willebrand Factor Proteins 0.000 title claims abstract description 13
- 229960001134 von willebrand factor Drugs 0.000 title claims abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 64
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 59
- 229920001184 polypeptide Polymers 0.000 claims abstract description 58
- 102100032290 A disintegrin and metalloproteinase with thrombospondin motifs 13 Human genes 0.000 claims abstract description 24
- 108091005670 ADAMTS13 Proteins 0.000 claims abstract description 24
- 108010033276 Peptide Fragments Proteins 0.000 claims abstract description 24
- 102000007079 Peptide Fragments Human genes 0.000 claims abstract description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 7
- 210000004369 blood Anatomy 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 20
- 230000003472 neutralizing effect Effects 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims description 12
- 238000003776 cleavage reaction Methods 0.000 claims description 11
- 230000007017 scission Effects 0.000 claims description 11
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000006386 neutralization reaction Methods 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 230000007131 anti Alzheimer effect Effects 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 230000009257 reactivity Effects 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 1
- 108010083526 asialo-von Willebrand Factor Proteins 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 208000035888 Immune-mediated thrombotic thrombocytopenic purpura Diseases 0.000 description 7
- 208000004886 acquired thrombotic thrombocytopenic purpura Diseases 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000011358 absorbing material Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000006957 competitive inhibition Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000009256 replacement therapy Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 208000022774 Congenital thrombotic thrombocytopenic purpura Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- -1 etc.) Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101800000620 Disintegrin-like Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- the present invention relates to the field of prescription pharmaceuticals. Specifically, an antibody against a specific cleavage enzyme (hereinafter sometimes referred to as ADAMTS-13) of a von Willebrand Factor (hereinafter sometimes referred to as vWF) involved in blood coagulation.
- ADAMTS-13 a specific cleavage enzyme
- vWF von Willebrand Factor
- the present antibody may be referred to as an anti-ADAMTS-13 antibody.
- the present invention relates to an polypeptide that includes the peptide and the epitope, and an antibody that recognizes the polypeptide.
- the polypeptide or peptide fragment containing the epitope region recognized by the antibody against ADAMTS-13 provided by the present invention can be used to diagnose autoantibodies to ADAMTS-13, or to absorb autoantibodies or autoantibodies to ADAMTS-13.
- the potential of ADAMTS-13 replacement therapy in patients with the disease is opened up. Background art
- vWF is produced by vascular endothelial cells and bone marrow megakaryocytes, and is a multimeric structure (molecular weight of 500 to 500 kDa) in which a single subunit consisting of 2050 amino acid residues (monomer about 250 kDa) is connected by an SS bond. It is a hemostatic factor that exists with 20,000 kDa a).
- the blood concentration is about 10 ng / m1, and the higher the molecular weight, the higher the specific activity.
- VWF functions as two major hemostatic factors, one as a carrier protein that binds to and stabilizes blood coagulation factor VIII, and the other as a subendothelial cell on the injured vessel wall. It is a function to form platelet thrombus by adhering and agglutinating platelets to tissues.
- TTP Thrombotic thrombocytopenic purpura
- thrombotic thrombosis in systemic arterioles and capillaries of the whole body. Associated mortality rates have increased about 3-fold over the years 1971-1199.
- the presence of a large amount of vWF in the platelet thrombus produced by immunohistology is considered to be a major factor in this pathogenesis.
- TTP is broadly divided into familial (congenital), which is thought to have a genetic predisposition, and acquired (idiopathic), which develops especially in adults.
- the multimeric structure of VWF in TTP patients is normal or has a high molecular weight. : L vW
- vWF vWF-cleaving protease
- TTP is deduced because the enzyme activity in plasma decreases for some reason, UL vWFM or L vWFM increases, platelet aggregation increases, and platelet thrombus is formed in blood vessels. Have been.
- the vWF-cleaving enzyme which is the active substance having the enzyme activity
- the domain composition of ADAMTS-13 is the presence of the Propeptide following the Signal peptide, followed by the RQRR sequence of the Furin cleavage motif, followed by the Metalloprotease domain containing the Reprolysin-type zinc chelating region consisting of the consensus sequence of HEXXHXXGXXHD. (Up to amino acid residue number 284 (P285X)). Then, through a Disintegrin-like domain (up to amino acid residue number 386 (W387X)) as found in the snake venom meta-mouth protease, it is considered to be generally important for molecular recognition.
- Tspl-l Tspl motif
- RGDS sequence one of the cell adhesion motifs region (up to amino acid residue number 580 (T581X)). It then consists of about 130 amino acid residues without any cysteine residues
- Spacer domain up to amino acid residue number 6887 (W688X)
- Tspl-2 to 8 Tspl-2 to 8
- a first object of the present invention is to identify neutralizing epitopes present on ADAMTS-13 and to provide a neutralized / absorbing material mainly for autoantibodies proposed by the method. It is an invention.
- a second object of the present invention is to provide a method for producing such a neutralizing / absorbing material.
- a third object of the present invention is to provide a use of such a neutralizing / absorbing material.
- a fourth object of the present invention is to provide a method for producing a full-length or partially modified molecule of a VWF-specific cleavage enzyme obtained by modifying such an epitope.
- a fifth object of the present invention is to provide a use of a full-length or partially modified molecule of a VWF-specific cleavage enzyme obtained by modifying such an epitope.
- v Plasma exchange therapy has been used as a treatment for patients with congenital deficiency of the WF-specific cleavage enzyme and patients with an antibody positive for the acquired enzyme. It is hoped that replacement therapy with products will be established.
- the administered enzyme loses its enzymatic activity by being neutralized by antibodies to the enzyme present in the patient's blood, that is, by autoantibodies. Typically the concentration is reduced.
- the method for determining the epitope of an antibody against ADAMTS-13 in the earlier application Japanese Patent Application No. 2002-279799
- the use of the neutralizing region identified in the present invention and By preparing a molecule having a partially modified neutralizing epitope region that can be newly identified by performing the Western blotting of the competitive inhibition method used in the present invention, administration to an antibody-positive patient against the enzyme is possible.
- the antibody can be absorbed by the polypeptide or the like containing the neutralizing region provided by the present invention. Disclosure of the invention
- JP-A-2003-284570 JP-A-2003-284570
- the purification and isolation of the desired vWF-cleaving enzyme was successful, and the amino acid sequence of the mature protein and the gene encoding the amino acid sequence were identified.
- Japanese Patent Application Laid-Open No. 2003-284570 Japanese Patent Application Laid-Open No. 2003-284570
- the autoantibody recognition region has the above activity.
- the region considered to be essential for expression it was clarified that the region exists from the Cys-rich region (about 499) to the Spacer region (about 687). Therefore, the resistance provided by the present invention
- the main requirements for the major neutralizing epitope region for the ADAMTS-13 antibody are the Cys-rich region (approximately 499-position) and the Spacer region (6
- the present invention includes a neutral epitope region of an von Willebrand factor-specific cleavage enzyme (hereinafter sometimes referred to as vWFCP or ADAMTS-13) recognized by the antibody.
- vWFCP von Willebrand factor-specific cleavage enzyme
- the present invention relates to a polypeptide consisting of the amino acid sequence from position 449 to position 687 of the amino acid sequence shown in SEQ ID NO: 1 or a peptide fragment derived from the polypeptide, which is represented by SEQ ID NO: 1.
- the amino acid sequence from position 449 to position 687 of the amino acid sequence A polypeptide comprising an amino acid sequence in which one or several amino acids have been deleted, substituted or added, and which is recognized by an antibody against a von Willebrand factor-specific cleavage enzyme or a peptide fragment derived from the polypeptide It is.
- one or several means one to five, preferably one to three, more preferably one or two.
- antibody preparation technology using phage display technology (Phage Display ⁇ Peptides and Proteins: A Laboratory Manual Edited by Brian K. Kay et al. (1996), Antibody Engineering: A PRACTICAL APPROACH Edited by J. McCAFFERTY et al. 1996) or ANTIBODY ENGINEERING second edition edited by Carl AK BORREBAECK (1995)) enables the production of antibodies that bind to the protein (ADAMTS-13).
- ADAMTS-13 ANTIBODY ENGINEERING second edition edited by Carl AK BORREBAECK (1995)
- the use of these antibodies makes it possible to apply the present invention to the diagnosis and treatment of diseases involving fluctuations in the amount of the enzyme, for example, diseases such as TTP.
- the present invention also includes these antibodies.
- the present invention relates to a method for diagnosing a patient at risk for a TTP-like disease or vWF-dependent thrombosis, comprising the following steps:
- Diagnostic assays for diseases involving fluctuations in this enzyme level are performed using biological samples from patients. These samples can be used directly or, in some cases, require treatment before performing the procedure, for example, removing potentially interfering substances in the sample. Can be. Examples of suitable biological samples are blood, urine, sweat, tissue or serum. The method comprises the steps of: Including detecting autoantibodies to the vWF-cleaving enzyme in the sample.
- the above-mentioned diagnosis can be performed by a known Imnoassay method, and a solid support such as a peas or a plate made of a resin such as polystyrene can be used.
- a solid support such as a peas or a plate made of a resin such as polystyrene
- the developing agent a radioisotope, peroxidase, Enzymes such as alkaline phosphatase, fluorescent substances and the like can be used.
- the polypeptide of the present invention is also useful as a neutralizing agent for autoantibodies by administration to an anti-ADAMTS-13 antibody-positive patient or as an autoantibody removing agent.
- neutralization of the autoantibodies means that the autoantibodies
- the polypeptide is optionally immobilized using methods known in the art, such as a suitable support.
- autoantibodies are removed from the patient sample by contacting the sample containing the anti-AD cliff TS-13 antibody to be removed, for example, the patient's blood with the immobilized polypeptide.
- the blood or plasma of the patient is brought into contact with the blood or plasma of the patient by contacting the carrier to which the ligand specific to the anti-ADATS-13 antibody is bound and the anti-ADATS-13 antibody in the blood or plasma.
- the antibody may be removed from the blood, and then the blood or plasma from which the antibody has been removed may be re-infused into the patient.
- the ligand specific to the anti-ADATS-13 antibody the above-mentioned polypeptide or a polypeptide fragment derived from the polypeptide can be used.
- the contact may be made, for example, by passing the patient's blood or plasma through a carrier to which the ligand is bound.
- the present invention relates to the step of contacting the blood or plasma of an anti-ADAMTS-13 antibody-positive patient with a carrier to which the above-described polypeptide or a peptide fragment derived from the polypeptide is bound, and then detecting the anti-ADATS-13 in the blood or plasma.
- An antibody is bound to the ligand and the antibody is removed from blood or plasma by
- Neutralizing agents for autoantibodies administered to patients with anti-ADAMTS-13 antibody positive An anti-dose containing a peptide or a peptide fragment derived from the polypeptide as an active ingredient
- ADAMTS-13 is a pharmaceutical composition for treating an antibody-positive patient. Further, a polypeptide or a peptide derived from the polypeptide in which the polypeptide or a peptide fragment derived from the polypeptide has lost reactivity with the anti-ADAMTS-13 antibody due to modification such as molecular substitution, deletion, or insertion. It is a pharmaceutical composition for treating a patient with anti-ADAMTS-13 antibody positive, which contains a fragment as an active ingredient.
- the modification such as molecular substitution, deletion, or insertion refers to, for example, deletion, substitution, or addition of one or more amino acids in the amino acid sequence of the polypeptide or the peptide fragment derived from the polypeptide. To be done.
- Such modifications may alter the structure of, for example, polypeptide or peptide fragments, resulting in an epi! Loss of activity results in loss of reactivity with anti-ADAMTS-13 antibody.
- a polypeptide that recognizes the anti-ADAMTS-13 antibody of the present invention is used as a neutralizing agent of the autoantibody by administration to an anti-AD cliff TS-13 antibody-positive patient, use a saline solution, a buffer solution, or the like. It can be diluted and formulated to give a pharmaceutical composition.
- the pH of the preparation is preferably weakly acidic to neutral pH close to the pH of the body fluid, and the lower limit is
- the preparation of the present invention may contain pharmacologically acceptable additives (eg, carriers, excipients, diluents, etc.), stabilizing agents, or components required for pharmacy, which are usually used for pharmaceuticals. .
- the stabilizer examples include monosaccharides such as glucose, disaccharides such as saccharose and maltose, sugar alcohols such as mannitol and sorbitol, neutral salts such as sodium chloride, amino acids such as glycine, polyethylene glycol, and polyoxyethylene-poly.
- Non-ionic surfactants such as oxypropylene copolymer (pluronic) and polyoxyethylene sorbitan fatty acid ester (tween), human albumin, etc. are exemplified, and about 1 to 10 wZv% may be added. preferable.
- the pharmaceutical composition of the present invention can be administered in an effective amount by intravenous injection, intramuscular injection, subcutaneous injection, etc., and is administered once or in several divided doses.
- the dosage varies depending on symptoms, age, weight, etc., but is preferably 0.001 mg to 100 mg per dose. Good.
- FIG. 1 is a diagram showing a method for producing a C-terminal deletion mutant for determining an epitope of an antibody.
- FIG. 2 is a photograph in which the expression of the prepared C-terminal deletion mutant was confirmed by Western plot under non-reducing conditions using an anti-FLAG antibody.
- FIG. 3 is a photograph in which a recognition region was confirmed by non-reducing Western blotting with purified IgG derived from an acquired TTP patient 003.
- FIG. 4 is a photograph in which the recognition region was confirmed by non-reducing Western plot with purified IgG derived from acquired TTP patient 2004.
- FIG. 5 is a photograph in which the recognition region was confirmed by non-reducing Western plot with purified IgG derived from an acquired TTP patient 009.
- FIG. 6 is a photograph showing confirmation of a more detailed recognition region of purified IgG derived from an acquired TTP patient.
- IgG fraction was prepared from the acquired patient plasma using a protein A column (antibody concentration of about 2-5 mg / m2). 1), it was diluted 200-fold and subjected to Western blotting. Filichiru was visualized by staining with a BCIPZNBT substrate using an anti-human IgG alkaline phosphatase-labeled antibody as a secondary antibody (FIGS. 3 to 5). The antibody recognition region determined in these manners reacted up to W688X and did not react with Q449X in any of the three antibody fractions, confirming that it was present on the C-terminal side of Q449X.
- the supernatant of the full-length wild type was electrophoresed and transferred to a PVDF membrane, and the above-mentioned patient antibody was concentrated in advance with a large excess of Q449X, W688X, or a concentrate of the full-length wild type expression supernatant.
- the W688X eliminated the full-length wild type positive band in all samples by the competitive inhibition system (Fig. 6).
- the results shown in Examples 1 and 2 indicate that the three autoantibodies used were mainly from the Cys-rich region to the Spacer region on the N-terminal side, ie, between Q449X and W688X, on the N-terminal side of W688X at the Q449X terminal side. It was confirmed that it was a sum area.
- the polypeptide of the present invention specifically shows immunoreactivity with an anti-ADAMTS-13 antibody. Therefore, rapid detection of the amount of the anti-ADAMTS-13 antibody, diagnosis of a disease associated with the fluctuation of the present enzyme, or neutralization of the binding or inhibitory activity of the anti-ADAMTS-13 antibody can be performed.
- the polypeptides provided by the present invention also provide a wide variety of uses including detection of anti-ADAMTS-13 antibodies.
- the present invention exerts such remarkable functions and effects, and it can be said that the present invention is a very significant invention that contributes to the art.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2519258A CA2519258C (en) | 2003-03-17 | 2004-03-17 | Construct comprising region recognized by antibody against von willebrand factor-specific cleaving protease |
EP04721377A EP1609804B1 (en) | 2003-03-17 | 2004-03-17 | Construct comprising recognition domain of antibody against von willebrand factor-specific cleaving enzyme |
US10/549,317 US7572591B2 (en) | 2003-03-17 | 2004-03-17 | Construct comprising recognition domain of antibody against von Willebrand factor-specific cleaving enzyme |
CN2004800135412A CN1791614B (zh) | 2003-03-17 | 2004-03-17 | 含抗von Willebrand因子特异性切割酶的抗体识别的结构域的构建体 |
JP2005503725A JP4680770B2 (ja) | 2003-03-17 | 2004-03-17 | フォンビルブランド因子特異的切断酵素に対する抗体の認識領域からなる構成物 |
AU2004221982A AU2004221982B2 (en) | 2003-03-17 | 2004-03-17 | Construct comprising recognition domain of antibody against von Willebrand factor-specific cleaving enzyme |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003071979 | 2003-03-17 | ||
JP2003-071979 | 2003-03-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004083250A1 WO2004083250A1 (ja) | 2004-09-30 |
WO2004083250A9 true WO2004083250A9 (ja) | 2005-02-03 |
Family
ID=33027710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/003602 WO2004083250A1 (ja) | 2003-03-17 | 2004-03-17 | フォンビルブランド因子特異的切断酵素に対する抗体の認識領域からなる構成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7572591B2 (ja) |
EP (1) | EP1609804B1 (ja) |
JP (1) | JP4680770B2 (ja) |
CN (1) | CN1791614B (ja) |
AU (1) | AU2004221982B2 (ja) |
CA (1) | CA2519258C (ja) |
WO (1) | WO2004083250A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7083786B2 (en) | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
US20040185042A1 (en) | 2003-03-20 | 2004-09-23 | Friedrich Scheiflinger | Immunoadsorption of anti-von Willebrand Factor cleaving protease antibodies |
US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US8685665B2 (en) | 2007-06-22 | 2014-04-01 | The Chemo-Sero-Therapeutic Research Institute | ADAMTS-13 mutant |
WO2009118660A2 (en) | 2008-03-24 | 2009-10-01 | Salman Rahman | Adam-15 antibodies and immunogenic peptides |
ES2617920T3 (es) * | 2009-10-16 | 2017-06-20 | Omeros Corporation | Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2 |
WO2012042391A2 (en) * | 2010-10-01 | 2012-04-05 | Salman Rahman | Methods for the development of metzincin-selective catalytic cleft directed antibodies for therapeutic and diagnostic applications |
US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
DK2694108T3 (en) | 2011-04-08 | 2018-08-20 | Univ Leicester | METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION |
WO2020219353A1 (en) * | 2019-04-26 | 2020-10-29 | Albert Einstein College Of Medicine | Red blood cells expressing von willebrand factor protease and methods of use thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874531A (en) | 1995-03-07 | 1999-02-23 | President And Fellows Of Harvard College | Identification of self and non-self antigens implicated autoimmune disease |
JP2003284570A (ja) | 2001-04-25 | 2003-10-07 | Chemo Sero Therapeut Res Inst | フォンビルブラント因子(vWF)切断酵素 |
DE60331666D1 (de) | 2002-09-25 | 2010-04-22 | Chemo Sero Therapeut Res Inst | Antikörper gegen ein den von-willebrand-faktor spezifisch spaltendes enzym und assay-system unter verwendung davon |
-
2004
- 2004-03-17 CN CN2004800135412A patent/CN1791614B/zh not_active Expired - Lifetime
- 2004-03-17 US US10/549,317 patent/US7572591B2/en active Active
- 2004-03-17 JP JP2005503725A patent/JP4680770B2/ja not_active Expired - Lifetime
- 2004-03-17 EP EP04721377A patent/EP1609804B1/en not_active Expired - Lifetime
- 2004-03-17 CA CA2519258A patent/CA2519258C/en not_active Expired - Lifetime
- 2004-03-17 WO PCT/JP2004/003602 patent/WO2004083250A1/ja active Application Filing
- 2004-03-17 AU AU2004221982A patent/AU2004221982B2/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
CN1791614A (zh) | 2006-06-21 |
US20060240476A1 (en) | 2006-10-26 |
EP1609804A1 (en) | 2005-12-28 |
EP1609804A4 (en) | 2006-07-05 |
AU2004221982B2 (en) | 2011-10-13 |
JP4680770B2 (ja) | 2011-05-11 |
AU2004221982A1 (en) | 2004-09-30 |
CN1791614B (zh) | 2011-01-12 |
EP1609804B1 (en) | 2012-06-13 |
CA2519258A1 (en) | 2004-09-30 |
WO2004083250A1 (ja) | 2004-09-30 |
CA2519258C (en) | 2014-04-22 |
US7572591B2 (en) | 2009-08-11 |
JPWO2004083250A1 (ja) | 2006-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2373691T3 (en) | ANTI-FXI ANTIBODIES AND PROCEDURES FOR USE | |
RU2636038C2 (ru) | Композиции для ингибирования masp-2-зависимой активации комплемента | |
EP0701569B1 (en) | Improved reagents and methods for the diagnosis and treatment of diabetes and stiff man syndrome | |
JP5226169B2 (ja) | Masp−2、すなわち補体固定酵素及びその使用 | |
JP2009236925A (ja) | フォンビルブランド因子特異的切断酵素を主成分とする診断薬および医薬品 | |
EP1674480A1 (en) | Antibody recognizing tgf-beta activation controlling region section | |
WO1994012529A9 (en) | Improved reagents and methods for the diagnosis and treatment of diabetes and stiff man syndrome | |
KR940002033B1 (ko) | 단백질 c에 대해 특이성이 있는 단클론성 항체 및 항체의 분리방법 | |
EA025220B1 (ru) | Фрагменты расщепления иммуноглобулинов в качестве индикаторов заболеваний, реагенты для их детекции и применения таких реагентов | |
JP4680770B2 (ja) | フォンビルブランド因子特異的切断酵素に対する抗体の認識領域からなる構成物 | |
EP3131929B1 (en) | Antibodies for the prevention or the treatment of bleeding episodes | |
EP0517817B1 (en) | Inhibitors of catalytic antibodies | |
JP4500494B2 (ja) | 第viii因子の抗原エピトープ、当該エピトープに対して向けられたインヒビターおよびそれらの使用 | |
JP4451518B2 (ja) | ハイブリッド細胞、モノクローナル抗体、製造方法および測定方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
COP | Corrected version of pamphlet |
Free format text: PAGE 1/7, DRAWINGS, ADDED |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005503725 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2519258 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006240476 Country of ref document: US Ref document number: 10549317 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004221982 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004721377 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004221982 Country of ref document: AU Date of ref document: 20040317 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004221982 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048135412 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004721377 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10549317 Country of ref document: US |